|本期目录/Table of Contents|

[1]张茂芃,陈炳伟,卢成志,等.脉冲场消融治疗心房颤动的短期及长期安全性临床研究[J].天津医科大学学报,2023,29(06):636-640.
 ZHANG Mao-peng,CHEN Bing-wei,LU Cheng-zhi,et al.The short-term and long-term safety clinical trial of pulse field ablation to treat atrial fibrillation[J].Journal of Tianjin Medical University,2023,29(06):636-640.
点击复制

脉冲场消融治疗心房颤动的短期及长期安全性临床研究(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
29卷
期数:
2023年06期
页码:
636-640
栏目:
临床医学
出版日期:
2023-11-20

文章信息/Info

Title:
The short-term and long-term safety clinical trial of pulse field ablation to treat atrial fibrillation
文章编号:
1006-8147(2023) 04-0636-05
作者:
张茂芃12陈炳伟3卢成志3薛志孝1
(1.天津医科大学生物医学工程与技术学院医学仪器教研室,天津300070;2.天津医科大学眼科医院设备科,天津300384;3.天津市第一中心医院心内科,天津300192)
Author(s):
ZHANG Mao-peng12CHEN Bing-wei3LU Cheng-zhi3XUE Zhi-xiao1
(1.Departmentof Medical Instruments, School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin 300070, China; 2.Equipmentdepartment, Eye Hospital, Tianjin Medical University, Tianjin 300384, China; 3.Department of Cardiology, Tianjin First Central Hospital, Tianjin 300192, China)
关键词:
脉冲场消融心房颤动肺静脉隔离
Keywords:
pulse field ablationatrial fibrillationvein isolation
分类号:
R541.7
DOI:
-
文献标志码:
A
摘要:
目的:评估脉冲场消融治疗用于心房颤动患者进行导管消融的短期及长期(6个月)安全性。方法:本研究是一项前瞻性、单臂的临床研究,纳入18~75岁临床明确诊断为症状性心房颤动的10例患者,使用脉冲消融治疗系统(天津市鹰泰利安康医疗科技有限责任公司)对患者进行脉冲消融治疗,评估受试者在手术即刻至术后6个月并发症的发生情况,检测患者生命体征、不良事件、严重不良事件的发生率以及手术后器械相关或手术相关不良事件的发生率。结果:本研究10例心房颤动患者中3例为持续性心房颤动,7例为阵发性心房颤动。平均总手术时间为(220.1±47.2)min;平均透视时间为(35.1±10.6)min;脉冲场消融导管在体内的平均停留时间为(69.1±8.3)min。无1例发生与消融导管相关的并发症。十二导联心电图未见房性或室性心动过速,亦未见明显复极异常。所有患者术后均无明显的胸椎或上肢肌肉不适或神经运动或感觉症状。所有患者在术后2 d内生命体征平稳,均未出现器械相关或手术相关重大不良事件及并发症,并且在术后6个月随访期间也未发生严重不良事件及相关并发症。结论:在脉冲场消融治疗后为期6个月的观察结果表明脉冲场消融治疗房颤具有短期及长期安全性,且脉冲场消融治疗可以实现组织选择性。
Abstract:
Objective: To evaluate the short-term and long-term safety of pulsed field ablation for catheter ablation in patients with atrial fibrillation(AF). Methods:This was a prospective, one-arm clinical study. Ten patients aged 18-75 years who were clinically diagnosed with symptomatic atrial fibrillation were enrolled in a pulsed ablation system(Tianjin Ying Tai Li An Kang Medical Technology Co., LTD.) to assess the incidence of complications from immediate surgery to 6 months after surgery. Vital signs, the incidence of adverse and serious adverse events were measured, as well as the incidence of instrument-related or surgery-related adverse events after surgery. Results:Among the 10 patients with AF in this study, 3 cases were persistent AF and 7 cases were paroxysmal AF. The mean total operation time was (220.1±47.2)min. The average perspective time was (35.1±10.6)min. The average residence time of pulsed field ablation catheter in vivo was (69.1±8.3)min. None of the complications related to catheter ablation occurred. ECG showed no atrial or ventricular tachycardia, and no significant repolarization abnormalities. None of the patients had significant thoracic or upper extremity muscle discomfort or neuromotor or sensory symptoms. All patients had stable vital signs 2 days after surgery,no instrument-related or surgery-related major adverse events or complications, and no serious adverse events or related complications during the 6-month follow-up. Conclusion:PFA(pulse field ablation)has short-term and long-term safety for AF during the observation for 6 months after pulse field ablation therapy,and PFA can achieve tissue selectivity.

参考文献/References:

[1] SEPEHRI SHAMLOO A,DAGRES N,HINDRICKS G. 2020 ESC guidelines on atrial fibrillation:summary of the most relevant recommendations and innovations[J]. Herz,2021,46(1):28-37.
[2] SAGRIS M,VARDAS E P,THEOFILIS P,et al. Atrial fibrillation:pathogenesis,predisposing factors,and genetics[J]. Int J Mol Sci,2021,23(1):6.
[3] PACKER D L,MARK D B,ROBB R A,et al. Effect of catheter ablation vs. antiarrhythmic drug therapy on mortality,stroke,bleeding,and cardiac arrest among patients with atrial fibrillation:the CABANA randomized clinical trial[J]. JAMA, 2019,321(13):1261-1274.
[4] DE POOTER J, STRISCIUGLIO T, EL HADDAD M, et al. Pulmonary vein reconnection no longer occurs in the majority of patients after a single pulmonary vein isolation procedure[J]. JACC Clin Electrophysiol, 2019,5(3):295-305.
[5] 赵志宏,陈永刚,宁忠平,等. 快速心律失常脉冲电场不可逆电穿孔消融治疗研究进展[J]. 中国医疗器械杂志,2021,45(5):517-523.
[6] 路桥,张先林,王洪巨. 脉冲场消融在房颤中的应用进展[J]. 实用心电学杂志,2021,30(5):322-327.
[7] BI S,JIA F,LV C,et al. Preclinical study of biphasic asymmetric pulsed field ablation[J]. Front Cardiovasc Med,2022,9:859480.
[8] 刘玉堂,韩玉,薛志孝. 高频不可逆电穿孔的消融参数与消融有效性关系的研究[J]. 天津医科大学学报,2020,26(2):108-113,117.
[9] WANG T J,LARSON M G,LEVY D,et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality:the Framingham Heart Study[J]. Circulation,2003,107(23):2920-2925.
[10] DELLO RUSSO A,FASSINI G,CONTI S,et al. Analysis of catheter contact force during atrial fibrillation ablation using the robotic navigation system:results from a randomized study[J]. J Interv Card Electrophysiol,2016,46(2):97-103.
[11] REDDY V Y,DUKKIPATI S R,NEUZIL P,et al. Pulsed field ablation of paroxysmal atrial fibrillation:1-year outcomes of IMPULSE,PEFCAT,and PEFCAT II[J]. JACC Clin Electrophysiol,2021,7(5):
614-627.
[12] WITT C M,SUGRUE A,PADMANABHAN D,et al. Intrapulmonary vein ablation without stenosis:a novel balloon-based direct current electroporation approach[J]. J Am Heart Assoc,2018,7(14):e009575.
[13] KORUTH J,KUROKI K,IWASAWA J,et al. Preclinical evaluation of pulsed field ablation:electrophysiological and histological assessment of thoracic vein isolation[J]. Circ Arrhythm Electrophysiol, 2019,12(12):e007781.
[14] YE X,LIU S,YIN H,et al. Study on optimal parameter and target for pulsed-field ablation of atrial fibrillation[J]. Front Cardiovasc Med,2021,8:690092.
[15] VERMA A,BOERSMA L,HAINES D E,et al. First-in-human experience and acute procedural outcomes using a novel pulsed field ablation system:the PULSED AF pilot trial[J]. Circ Arrhythm Electrophysiol,2022,15(1):e010168.
[16] ANDRADE J G,CHAMPAGNE J,DUBUC M,et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring:a randomized clinical trial[J]. Circulation,2019,140(22):1779-1788.

相似文献/References:

[1]王爱芬,崔利军,马向红.非瓣膜性心房颤动左心房/左心耳血栓形成的相关因素分析[J].天津医科大学学报,2015,21(02):130.
 WANG Ai-fen,CUI Li-jun,MA Xiang-hong.Related factors of left atrial or left atrial appendage thrombus formation in patients with non-valvular atrial fibrillation[J].Journal of Tianjin Medical University,2015,21(06):130.
[2]陈延勋,李广平. 非瓣膜性心房颤动患者尿酸与CHADS2、CHA2DS2-VASc评分的关系[J].天津医科大学学报,2015,21(03):185.
 CHEN Yan-xun,LI Guang-ping. Relationship between uric acid and CHADS2/CHA2DS2-VASc Score in patients with nonvalvular atrial fibrillation[J].Journal of Tianjin Medical University,2015,21(06):185.
[3]崔占前,徐延敏.脂蛋白相关性磷脂酶A2及高敏C反应蛋白与左心房内径的关系[J].天津医科大学学报,2015,21(03):196.
 CUI Zhan-qian,XU Yan-min.Relationship between plasma lipoprotein-associated phospholipase A2, high sensitivity C reactive protein and left atrial diameter[J].Journal of Tianjin Medical University,2015,21(06):196.
[4]付伟伟,李国东,王 喆.HDL-C与非瓣膜性心房颤动左心房/左心耳血栓形成的关系[J].天津医科大学学报,2015,21(06):498.
 FU Wei-wei,LI Guo-dong,WANG Zhe.Relationship between high-density lipoprotein cholesterol and left atrial / left atrial appendage thrombus in non-valvular atrial fibrillation patients[J].Journal of Tianjin Medical University,2015,21(06):498.
[5]张彦月,林文华.vWF及血浆D-二聚体水平对非瓣膜性心房颤动患者血栓形成的诊断及临床预后价值[J].天津医科大学学报,2016,22(02):101.
 ZHANG Yan-yue,LIN Wen-hua.Value of vWF and?D-dimer for thrombosis and prognosis in patients with non-valvular atrial fibrillation[J].Journal of Tianjin Medical University,2016,22(06):101.
[6]刘运龄,赵艳淑,刘恩照,等.不同类型心房颤动患者心脏结构及B型钠尿肽水平的变化[J].天津医科大学学报,2016,22(06):522.
 LIU Yun-ling,ZHAO Yan-shu,LIU En-zhao,et al.Relationship between plasma leves B-type natriuretic peptide and cardiac structure in patients with different types of atrial fibrillation[J].Journal of Tianjin Medical University,2016,22(06):522.
[7]张邦滢 综述,李广平 审校.新型抗心律失常药物在心房颤动中的应用[J].天津医科大学学报,2017,23(01):90.
[8]张凤环,上官文锋,王学文,等.血管紧张素-(1-7)对快速心房起搏犬心房重构及p38MAPK蛋白表达的影响[J].天津医科大学学报,2019,25(05):450.
 ZHANG Feng-huan,SHANGGUAN Wen-feng,WANG Xue-wen,et al.Effect of angiotensin-(1-7) on atrial remodeling and p38MAPK expression in a canine model of rapid atrial pacing[J].Journal of Tianjin Medical University,2019,25(06):450.
[9]杜春蕾,郭 牧,张云强,等.尼非卡兰和胺碘酮治疗急性心肌梗死新发房颤有效性和安全性对比研究[J].天津医科大学学报,2019,25(05):471.
 DU Chun-lei,GUO Mu,ZHANG Yun-qiang,et al.Comparison of nifekalant and amiodarone in the treatment of new-onset atrial fibrillation in acute myocardial infarction patients[J].Journal of Tianjin Medical University,2019,25(06):471.

备注/Memo

备注/Memo:
作者简介 张茂芃(1990-),男,硕士在读,研究方向:生物医学工程;通信作者:卢成志,E-mail:5020200072@nankai.edu.cn;薛志孝,E-mail:xuezhixiao@126.com。
更新日期/Last Update: 2023-12-01